Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Empagliflozin/linagliptin/metformin - Boehringer Ingelheim/Eli Lilly and Company

Drug Profile

Empagliflozin/linagliptin/metformin - Boehringer Ingelheim/Eli Lilly and Company

Alternative Names: Empagliflozin/linagliptin/metformin extended release; Empagliflozin/metformin/linagliptin; EmpaLinaMet XR; Linagliptin/empagliflozin/metformin; Linagliptin/metformin/empagliflozin; Metformin/empagliflozin/linagliptin; Metformin/linagliptin/empagliflozin; Trijardy™ XR

Latest Information Update: 31 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Boehringer Ingelheim; Eli Lilly and Company
  • Class Antihyperglycaemics
  • Mechanism of Action AMP activated protein kinase stimulants; Dipeptidyl peptidase 4 inhibitors; Gluconeogenesis inhibitors; Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Type 2 diabetes mellitus

Most Recent Events

  • 28 Jan 2020 Registered for Type 2 diabetes mellitus in USA (PO)
  • 28 Jan 2020 Trijardy XR has a boxed warning for the risk of lactic acidosis
  • 28 Jan 2020 Adverse events data from a phase III trial in Type 2 diabetes released by Eli Lilly and Boehringer Ingelheim
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top